AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00098813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV
Study NCT00098813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00098813 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies
Study NCT02061371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual therapy
Study NCT02061371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Study NCT01610778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01610778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid phosphate
Study NCT03743857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: AP ankle mobilization
Study NCT03777748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implants and stud attachments
Study NCT01588392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short bouts of structured physical activity
Description: Short bouts of structured physical activity preschools will be asked to implement age-appropriate 10 minute structured physical activity routines within the classroom setting followed by 20 minutes of usual unstructured playtime activities. Intervention will be implemented for a total of 30 minutes during both morning and afternoon gross motor playtime 5 days/week for 6 months.
Study NCT01588392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured physical activity
Description: Unstructured physical activity intervention will consist of 30 minutes of supervised unstructured free playtime twice. intervention will be delivered during both morning and afternoon gross motor playtime for 5 days/week for 6 months.
Study NCT01993121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Training
Description: All subjects will perform three months of supervised exercise training.
Study NCT00001213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine
Study NCT00687375 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Inguinal Hernia Repair
Description: Laparoscopic Inguinal Hernia Repair using Transabdominal preperitoneal (TAPP) Approach
Study NCT00687375 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Inguinal Hernia Repair
Description: Laparoscopic Inguinal Hernia Repair using totally extra peritoneal (TEP) Approach
Study NCT03079843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to particulate matter with N 95 facemask
Description: 2 hours' / day exposure to particulate matter face mask worn during exposure.
Study NCT03079843 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exposure to particulate matter with no face mask
Description: 2 hours'/ day exposure to particulate matter with no face mask
Study NCT03925779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine sedation
Study NCT03925779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: propofol sedation
Study NCT03925779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Remifentanil sedation
Study NCT02004041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLY-686
Study NCT02004041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01957306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dr. Tagliaferri's Menopause Formula
Description: Administered as 2 grams PO BID
Study NCT03623529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LJPC-501 (angiotensin II)
Description: Angiotensin II is a peptide hormone naturally produced by the body that regulates blood pressure via vasoconstriction and sodium reabsorption.
Study NCT03623529 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Arm
Study NCT00792168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: venlafaxine (Effexor)
Description: venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
Study NCT00792168 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
Study NCT03085602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Therapy focused on explaining the physiological and psychological effects of nicotine. Training is focused on adherence to smoking instructions, physiological and psychological effects of nicotine, reviewing reasons for quitting, and coping with smoking urges. Smokers will be asked to begin smoking on a set schedule leading up to their quit day.
Study NCT03085602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Therapy that provides health education on the importance of healthy eating. Participants will be instructed to smoke as usual.
Study NCT03105752 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire of understanding
Description: The study involved 12 clinical trials conducted in the Clinical Research Center Paris Est. Twenty participants per trial were offered to answer the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) at the inclusion visit after receiving the information by the investigator and signed or refused to sign the form of consent.~Participants filled out the questionnaire in an isolated location, with no possibility of re-reading the information contained in the consent form. The questionnaire was immediately retrieved.
Study NCT03933085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Support System (MSS)
Description: A calendar/notetaking system focused on training a person with MCI to use a specific external memory compensatory strategy to complete relevant IADLs independently.
Study NCT02779556 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ACP Living with Diabetes Guide
Description: American Colleges of Physicians (ACP) Living Well with Diabetes Guide
Study NCT02779556 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ADA Living Well with Diabetes Workbook
Description: American Diabetes Association (ADA) Living Well with Diabetes Workbook
Study NCT00622440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AIJP (Arnebia Indigo Jade Pearl)
Description: Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
Study NCT00622440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice daily for 48 weeks.
Study NCT04151303 — intervention group
Intervention type: PROCEDURE
Intervention: Cervical cerclage
Description: Cervical cerclage and cervical cerclage removal
Study NCT03770988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Poziotinib
Description: Treatment with Poziotinib
Study NCT03371043 — intervention group
Intervention type: OTHER
Intervention: users of analgesic medications
Description: Children and adolescents who are users of analgesic medications, 2012 to 2015
Study NCT03333772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REAL-T Intervention
Description: Individualized lifestyle intervention conducted via internet-based videoconferencing and incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants will have approximately 6-10 sessions lasting about one hour each, over a 3-month period.
Study NCT01895556 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information
Study NCT01895556 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study NCT05125588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reumoxicam® 15 mg tablets (PJSC Farmak, Ukraine)
Description: One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
Study NCT05125588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Movalis 15 mg tablets (Boehringer Ingelheim Ellas A.E., Greece)
Description: One tablet was administered orally and swallowed at once, without chewing, by study volunteers, followed by 200 ml of water, under fasting condition (after preliminary nocturnal fasting for 12 hours) in the morning at 8:00 hours on Day I Period I and Period II of the study.
Study NCT00891670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: 100mg twice daily for at least 1 month
Study NCT00891670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: 75mg once daily (triple group arm)~150mg once daily (high maintenance dose group arm)
Study NCT00891670 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: aspirin 100mg
Study NCT01652534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine
Description: Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day. Amantadine will then be administered orally twice daily in the morning with breakfast and at noon with lunch (AM and NN).
Study NCT01652534 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar Pill
Study NCT00731302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin and meloxicam
Description: aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily
Study NCT03855488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard cognitive bias modification
Description: Participants will be asked to repeatedly listen to descriptions of ambiguous scenarios that resolve positively and answer one question following each scenario that reinforces the positive interpretation; participants will listen to 60 scenarios/day for 7 days.
Study NCT03855488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery enhanced cognitive bias modification
Description: Participants will be asked to imagine themselves as though they are actively involved in the scenarios that they listen to. This condition will be required to answer two questions following each scenario; one that reinforces the positive interpretation and another that promotes engagement with imagery. Participants will listen to 60 scenarios/day for 7 days.
Study NCT03855488 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Neutral Control Condition
Description: Participants will be asked to listen to descriptions of neutral (i.e., non-emotional) scenarios. This condition will also be required to answer one comprehension question following each scenario. Participants will listen to 60 scenarios/day for 7 days.
Study NCT03067714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula with added synbiotics
Description: Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
Study NCT03067714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant formula
Description: Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
Study NCT01662570 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Beverage Choice and Lifestyle Modification
Description: The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake. 16 sessions were provided over a 6-month period.
Study NCT01662570 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition Education (NE)
Description: This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included. 16 sessions over 24 weeks was provided.
Study NCT00455182 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Standard medical care plus a single true acupuncture treatment.The needles are strategically inserted into the scalp, trunk, arms or legs (not near the surgical site) and manipulated. The needles are withdrawn between 5 minutes and 30 minutes after insertion.
Study NCT00455182 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Standard medical care plus sham acupuncture. A single treatment, using a maximum of 9 sham needles, which adhere to the skin but do not penetrate it. The sham needles are strategically placed on the scalp, trunk, arms or legs (not near the surgical site)
Study NCT00455182 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care at Woodwinds Hospital includes guided imagery, essential oils and massage.
Study NCT02231931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: single dose, fasted
Study NCT02231931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: single dose, fasted
Study NCT02231931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin
Description: fasted
Study NCT02231931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride
Description: single dose, fasted
Study NCT02231931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: single dose, fasted
Study NCT01032122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
Study NCT02586740 — intervention group
Intervention type: PROCEDURE
Intervention: Pulmonary artery rehabilitation
Study NCT00912795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Turkey
Description: 6-week smoking cessation program delivered via daily text messages~SMS Turkey: 6-week smoking cessation program delivered via text messaging. SMS Turkey content is guided by the Cognitive Behavioral Therapy (CBT) theory.~Content was tailored based on participant's stage in quitting (i.e., pre-quit, quit day, early-quit, late-quit, relapse). Based on the typical relapse trajectory, content paths were created for participants based on whether or not they were smoking 2 days after quit day; and again at 7 days after quit day.~Depending on the participant's content path, the total number of messages received ranged from 91 (for those assigned to the encouragement arm) to 146 (for those who relapsed and then were assigned to the late quit messages).
Study NCT00176917 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains the enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e. blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
Study NCT00176917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan, Cyclophosphamide, ATG
Description: Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.
Study NCT04014517 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care is represented by the best standard peri-operative treatment already planned for the study population: as for ERAS guidelines, it is represented by fast restoration of liquid and solid diet after surgery (approximately 24 hours after surgery) and pre-operative and post-operative dietary counselling whenever indicated by the surgeon or gastroenterologist
Study NCT04014517 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition
Description: Impact. Patients will be asked to consume 3 cartons/day of Nestle IMPACT for pre-operative 7 days and 1 carton/day of Nestle IMPACT for post-operative 30 days
Study NCT03731676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed bearing total knee arthroplasty
Description: Fixed bearing total knee arthroplasty
Study NCT03731676 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rotating platform total knee arthroplasty
Description: Rotating platform total knee arthroplasty
Study NCT04365608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscopy
Description: standard laryngoscope with Macintosh blade
Study NCT04365608 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vie Scope laryngoscopy
Description: Vie Scope with dedicated bougie stylet
Study NCT02476461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: xiapex
Study NCT02476461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous needle fasciotomy
Study NCT03860259 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Auriculotherapy cryopuncture device without nitrogen gas
Description: Auriculotherapy cryopuncture device without nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
Study NCT03860259 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auriculotherapy cryopuncture device with nitrogen gas
Description: Auriculotherapy cryopuncture device with nitrogen gas will be administered. In addition, an interscalene block will be performed as well as standard of care treatment for surgery, post-operative pain management and physical therapy
Study NCT01134055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib eye drops
Description: A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
Study NCT01134055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo eye drops
Study NCT03614520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol free Beer
Description: 250 mL of alcohol free beer (alcohol 0.0% vol)
Study NCT01849042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ebixa
Description: add-on of Ebixa oral pump already receiving donepezil with stable dosage
Study NCT01849042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: donepezil
Study NCT01849042 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: donepezil
Study NCT01134055 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab intravitreal injection
Description: Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
Study NCT02918513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 1 - Exercise
Description: 1. Daily wellness element focusing on Exercise; adherence documented online daily
Study NCT02918513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 2 - Mindfulness
Description: 2. Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
Study NCT02918513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 3 - Sleep Hygiene
Description: 3. Daily wellness element focusing on sleep hygiene; adherence documented online daily